Why compare it with chemotherapy alone when it should be compared with standard targeted therapy? There are too many drugs more effective than chemotherapy alone, which simply cannot demonstrate an advantage over the current standard treatment.
Summit Therapeutics Reveals Promising Phase III Trial Results
Summit Therapeutics (SMMT) announced promising Phase III trial results for ivonescimab, showing improved overall survival in EGFR-mutated non-small cell lung cancer patients when combined with chemotherapy. The trial results were presented at the World Conference on Lung Cancer, indicating potential changes in cancer treatment. Analysts rate SMMT stock as a Buy with a $30 price target, though Spark's AI Analyst suggests a Neutral stance due to financial challenges. The company focuses on developing novel cancer therapies and has a market cap of $19.3B.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
